1. Home
  2. NMM vs AGIO Comparison

NMM vs AGIO Comparison

Compare NMM & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Navios Maritime Partners LP

NMM

Navios Maritime Partners LP

HOLD

Current Price

$91.53

Market Cap

2.2B

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$32.92

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMM
AGIO
Founded
2007
2007
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.0B
IPO Year
2007
2013

Fundamental Metrics

Financial Performance
Metric
NMM
AGIO
Price
$91.53
$32.92
Analyst Decision
Strong Buy
Buy
Analyst Count
1
8
Target Price
★ $85.00
$38.88
AVG Volume (30 Days)
129.3K
★ 736.0K
Earning Date
05-05-2026
04-29-2026
Dividend Yield
★ 0.34%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $43,011,000.00
Revenue This Year
$5.57
$76.75
Revenue Next Year
$3.66
$170.73
P/E Ratio
$7.24
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$43.02
$22.24
52 Week High
$95.00
$46.00

Technical Indicators

Market Signals
Indicator
NMM
AGIO
Relative Strength Index (RSI) 57.52 44.44
Support Level $69.21 $32.43
Resistance Level $91.96 $35.88
Average True Range (ATR) 2.11 1.37
MACD -0.67 -0.01
Stochastic Oscillator 53.94 33.46

Price Performance

Historical Comparison
NMM
AGIO

About NMM Navios Maritime Partners LP

Navios Maritime Partners LP is an international owner and operator of dry cargo and tanker vessels. Its vessels are generally chartered-out under short-term, medium-term and long-term time charters with an average remaining charter duration of approximately 2.1 years to a group of counterparties. Its fleet consisted of dry bulk vessels, containerships and tanker vessels, including two newbuilding capesize vessels, newbuilding containerships and newbuilding tankers. It operates in single segment.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: